27776794|t|Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo
27776794|a|Interleukin-15 has become a promising molecule in the context of eliciting an effective, antitumor immune response because it is able to stimulate cells of the innate and adaptive immune system. We generated an interleukin-15 - expressing oncolytic influenza A virus for the treatment of an established murine tumor model. Our oncolytic influenza A virus produced large amounts of interleukin-15 and induced proliferation and activation of human T cells in vitro. Intraperitoneal administration increased the amount of mouse natural killer cells and effector memory T cells, as well as T cell reactivity in vivo. Moreover, intratumoral injection induced a profound decrease in growth of established tumors in mice and increased the amount of tumor-infiltrating T cells and natural killer cells. We established a stable, IL-15 -producing oncolytic influenza A virus with promising immunostimulatory and antitumor attributes.
27776794	0	9	Oncolytic	T080	C1518581
27776794	10	27	influenza A virus	T005	C0029347
27776794	28	38	expressing	T045	C1171362
27776794	39	53	interleukin-15	T116,T129	C0254610
27776794	54	63	decreases	T081	C0547047
27776794	64	76	tumor growth	T191	C0598934
27776794	77	84	in vivo	T082	C1515655
27776794	85	99	Interleukin-15	T116,T129	C0254610
27776794	163	172	effective	T080	C1704419
27776794	174	183	antitumor	T042	C1516031
27776794	184	199	immune response	T042	C0301872
27776794	222	251	stimulate cells of the innate	T040	C2248889
27776794	256	278	adaptive immune system	T040	C2256192
27776794	296	310	interleukin-15	T116,T129	C0254610
27776794	313	323	expressing	T045	C1171362
27776794	324	333	oncolytic	T080	C1518581
27776794	334	351	influenza A virus	T005	C0029347
27776794	360	369	treatment	T169	C0039798
27776794	388	406	murine tumor model	T050	C0012644
27776794	412	421	oncolytic	T080	C1518581
27776794	422	439	influenza A virus	T005	C0029347
27776794	466	480	interleukin-15	T116,T129	C0254610
27776794	493	506	proliferation	T043	C0596290
27776794	511	538	activation of human T cells	T043	C2259065
27776794	539	547	in vitro	T080	C1533691
27776794	549	579	Intraperitoneal administration	T169	C1522583
27776794	580	589	increased	T081	C0205217
27776794	604	630	mouse natural killer cells	T025	C1524008
27776794	635	658	effector memory T cells	T025	C4289596
27776794	671	677	T cell	T025	C0039194
27776794	678	688	reactivity	T169	C0443286
27776794	689	696	in vivo	T082	C1515655
27776794	708	720	intratumoral	T169	C2960749
27776794	721	730	injection	T061	C1533685
27776794	741	749	profound	T080	C0439808
27776794	750	758	decrease	T081	C0547047
27776794	762	790	growth of established tumors	T191	C0598934
27776794	794	798	mice	T015	C0025914
27776794	803	812	increased	T081	C0205217
27776794	827	853	tumor-infiltrating T cells	T025	C0079722
27776794	858	878	natural killer cells	T025	C0022688
27776794	905	910	IL-15	T116,T129	C0254610
27776794	922	931	oncolytic	T080	C1518581
27776794	932	949	influenza A virus	T005	C0029347
27776794	965	982	immunostimulatory	T040	C1817421
27776794	987	1007	antitumor attributes	T042	C1516031